October #64 : Talking Tipranavir - by Tim Horn

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Archives » POZ Magazine issues




Table of Contents

Stephen Gendin

Be Very Afraid

The CD4 Solution?

The Boys in the Band

Bare Witness

The March

My, What a Big Trial IL-2 Has! Will It Work?

AIDSplotation or Art?

Refugee All-Stars

Drive-By Shopping

Upward Mobility

S.O.S

NEG/POS

Take Five

POZ Picks

The Medium Is The Message

A Conference Of Their Own

Milestones

Cutting Class

Last Word

It Takes A Village Voice

Conference of the Century

Stop and Start

Sit Up, Sit Down?

Too Much Information

Sex RX

Talking Tipranavir

Shelf Life

The In Crowd

Herb Of The Month

He Died Of Old AIDS

10.8.88: Old Flames



Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV


email print

October 2000

Talking Tipranavir

by Tim Horn

If promise alone could bring new HIV drugs to marker, tipranavir would have already been approved, bottled, and gracing the shelf of a pharmacy near you. This protease inhibitor (PI), originally developed by Pharmacia & Upjohn and recently purchased by Boehringer Ingelheim, is just entering a Phase II studies but is already being heralded as the next best thing for people with HIV at the end of their protease rope.

Tipranavir binds to HIV’s protease gene differently from now the current PIs do and, according to recent lab studies, is active against some of the toughest drug-resistant strains of the virus. But the amount of tipranavir it takes to topple HIV in a test tube is difficult to achieve in humans; because the drug speeds up the biological pathway responsible for drug metabolism, high doses need to be taken up to three times a day. Knowing that fed-up med-takers will find it hard to swallow, Boehringer is fine-tuning a new formulation.

“Tipranavir will also need to be used in combination with low doses of ritonavir [Norvir],” explained Boehringer’s head of virology and immunology, Stephen Polmar, MD, PhD. ‘Once we’ve studied the new formulation and figured out its correct dose in combination with ritonavir, we can begin enrolling studies involving patients with multiple PI failures.” At this time, studies involving folks with multiple PI resistance are not expected to begin until mid-2001; FDA approval won’t likely be granted until 2003.

The delays in developments have come with a cost. “In addition to formulation problems the acquisition of the drug Boehringer from Pharmacia has set back the clinical trials timestable by at least a year,” says Linda Grindberg, founder of the Foundation of AIDS and Immune Research (FAIR) in Los Angeles and member of the all-activist Coalition for Salvage Therapy. ‘We hope these obstacles can be overcome quickly, but at this point, the drug’s utility is all conjecture.




[Go to top]

Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    dlw8585
    Fort Lauderdale
    Florida


    Sloan1
    Dallas
    Texas


    hollywoodvers1
    Los Angeles
    California


    pozsmith1
    East Bay
    California
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Do you work with your doc to design your own treatment regimen?
Yes
No

Survey
PrEP Course

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.